• 11 Feb 2020

SP Angel Healthcare Conditions

Hemogenyx Pharmaceuticals, 1.2 | e-Therapeutics, 8.8

    • Vadim Alexandre

    • 3 pages

Biotechnology image


 
Biotechnology image


Hemogenyx Pharma (HEMO.L): Approval of Hu-PHEC cell therapy patent | e-therapeutics (ETX.L): Board restructuring


Sign up to access

Get access to our full offering from over 30 providers

Get access to our full offering from over 30 providers


Get Started
Already a member? Log in here

More Content

More Content

e-Therapeutics PLC using its drug discovery platform in search for COVID-19 vaccine

Companies: e-Therapeutics

Riccardo Lowi on e-Therapeutics PLC

Companies: e-Therapeutics

e-Therapeutics PLC using its drug discovery platform in search for COVID-19 antivirals

Companies: e-Therapeutics

e-Therapeutics continuing to convert business development into cash generating partnerships

Companies: e-Therapeutics

SP Angel Healthcare Conditions

Companies: e-Therapeutics

Copyright © 2020 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Tools licensed and contents implemented and optimized by Digital Look Ltd.

DigitalLook |Web Financial Group

©1999-2013 – Digital Look Ltd. A Web Financial Group Company All rights reserved. Legal notice.

Top